Artivion (NYSE:AORT) Releases Earnings Results, Beats Expectations By $0.04 EPS

Artivion (NYSE:AORT) posted its quarterly earnings results on Monday. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04, Yahoo Finance reports. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. During the same quarter in the previous year, the company earned $0.02 earnings per share. Artivion updated its FY 2024 guidance to EPS.

Artivion Price Performance

Shares of Artivion stock traded up $2.88 during trading on Tuesday, reaching $23.95. 217,142 shares of the company’s stock were exchanged, compared to its average volume of 212,812. Artivion has a 1-year low of $12.16 and a 1-year high of $25.51. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.43 and a current ratio of 4.85. The firm’s 50-day moving average price is $20.40 and its 200 day moving average price is $18.06. The company has a market cap of $986.74 million, a P/E ratio of -31.69 and a beta of 1.66.

Analyst Upgrades and Downgrades

AORT has been the subject of several research analyst reports. Needham & Company LLC lifted their target price on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus upped their price objective on shares of Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday.

Insider Activity

In related news, VP Rochelle L. Maney sold 2,315 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $20.27, for a total value of $46,925.05. Following the completion of the transaction, the vice president now owns 39,197 shares in the company, valued at approximately $794,523.19. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, VP Rochelle L. Maney sold 2,315 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.27, for a total value of $46,925.05. Following the sale, the vice president now directly owns 39,197 shares in the company, valued at $794,523.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James P. Mackin sold 72,069 shares of Artivion stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $18.85, for a total transaction of $1,358,500.65. Following the transaction, the chief executive officer now directly owns 539,036 shares of the company’s stock, valued at approximately $10,160,828.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,952 shares of company stock worth $2,891,627. Corporate insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.